Pfizer, Roche Join $14.6M Financing for Mass Cytometry Startup DVS Sciences

July 15, 2011

Upstart cytometry firm DVS Sciences announced this week that it has closed a $14.6 million Series A financing round aimed at expanding commercialization of its CyTOF-Maxpar mass cytometry platform.

According to founder and CEO Scott Tanner, the funds will go primarily toward ramping up production of CyTOF instruments at the company's Markham, Ontario, headquarters; reagent production at a Sunnyvale, Calif., facility it formally opened this week; and the establishment of a global sales and service team. Read more>>>>